Physician profile
Fareed Shaikh
NPI 1609990779
$6,483.04
in general payments reported to CMS, 2019-2025
31 companies · $1,641 in 2025
The $1,641 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $200 · 2021: $793 · 2022: $1,195 · 2023: $1,003 · 2024: $1,446 · 2025: $1,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,973 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,973.41 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $661.42 | 2019-2025 | Farxiga, Brilinta |
| Abbott Laboratories | $642.14 | 2019-2025 | Diamondback Coronary, Pressurewire, Xience Skypoint |
| Amgen INC. | $639.84 | 2020-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $576.69 | 2020-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $484.38 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.48 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $391.75 | 2020-2024 | Xarelto |
| Abiomed | $304.51 | 2021-2025 | Impella |
| Novo Nordisk INC | $294.24 | 2023-2025 | Ozempic, Wegovy |
| Pfizer INC. | $250.71 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $247.35 | 2023-2025 | Camzyos, Eliquis |
| Cardiva Medical, INC. | $241.49 | 2023-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade Mvp Xl Vvcs 10-12f, Optowire |
| Boston Scientific Corporation | $222.10 | 2022-2025 | Avvigo Guidance System, Bodyguardian |
| Kestra Medical Technology Services, INC. | $144.48 | 2024-2025 | Assure Wcd |
| Inari Medical, INC. | $144.17 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $131.70 | 2022-2023 | |
| Chiesi USA, INC. | $115.72 | 2024-2025 | Kengreal |
| Shockwave Medical, INC | $90.68 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Cardiovascular Systems INC. | $71.56 | 2019-2021 | |
| Teleflex LLC | $65.40 | 2021-2025 | Guideliner, Turnpike |
| Medtronic, INC. | $56.54 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $50.10 | 2024-2025 | Uptravi, Opsumit |
| Kiniksa Pharmaceuticals International, Plc | $47.10 | 2024 | Arcalyst |
| Biotronik INC. | $46.75 | 2019-2023 | Recross, Pk Papyrus, Trapit |
| Octapharma USA, INC. | $32.56 | 2025 | Balfaxar |
| Esperion Therapeutics, INC. | $28.59 | 2020 | |
| Angiodynamics, INC. | $26.74 | 2021 | |
| Penumbra, INC. | $24.54 | 2025 | Indigo System |
| Astellas Pharma US INC | $22.74 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $21.64 | 2024 | |
| Sanofi-Aventis U.S. LLC | $12.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fareed Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.